Instituto Oncologico Dr. Rosell S.L. — Clinical Trial Site

19 Registered trials

7 Currently recruiting

Organisation

Instituto Oncologico Dr. Rosell S.L.

Location

Barcelona, Spain

Identifier

ORG-100033419

Address

Calle De Sabino Arana Num. 5, 08028, Spain

Departments

#7003: Oncology
034-03: Oncology
Medical oncology
Medical Oncology Department
Oncology
Servicio de Oncologia medica

Clinical trials at this site (19)

Search interface

Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma Pending

2025-525158-20-00 Stage IIB/C, Stage III, or Stage IV Melanoma 1
A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting

2025-523742-27-00 Advanced solid tumors 9 2026-04-28
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Metastatic Non-Small-Cell Lung Cancer 4 2025-12-19
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting

2025-522107-18-00 Locally advanced or metastatic Non-Small Cell Lung Canc 4 2026-05-19
A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer Recruiting

2025-524168-39-00 Platinum-Resistant ovarian cancer 1 2026-04-13
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Novo metastatic hormone-sensitive prostate cancer (mHSP 5 2024-09-04
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy… Ended

2023-506393-12-00 Advanced non-small cell lung cancer 1 2024-02-13
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 7 2023-11-27
A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended

2022-501576-25-00 Melanoma 5 2023-07-07
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors Ended

2023-509605-77-00 Advanced solid tumours 1 2019-06-27
A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer Ended

2024-519044-32-00 Advanced/Recurrent Ovarian cancer 9 2025-08-06
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended

2023-504630-22-00 Non-Small Cell Lung Cancer 7 2024-04-19
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended

2024-511996-13-00 Previously untreated, unresectable, or metastatic melan 5 2022-05-11
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended

2023-507389-15-00 Advanced Melanoma 4 2020-02-26